| Objective:By observing and analyzing the serum uric acid level of sacubitril valsartan in patients with chronic heart failure and hyperuricemia after treatment,to evaluate the effectiveness of the drug,so as to provide new ideas and strong evidence for the treatment of patients with chronic heart failure and hyperuricemia.Methods:This study is a retrospective study and has passed the ethics review of Anhui Provincial Hospital.A total of 108 inpatients with chronic heart failure complicated with hyperuricemia diagnosed in the First Affiliated Hospital of USTC(Anhui Provincial Hospital)from November 2021 to June 2022 were selected.According to the medication,the patients were divided into control group(n = 41)and observation group(n = 67).The gender,age,BMI,history of diabetes,history of hypertension,history of coronary heart disease and current use of drugs were collected,and the serum uric acid(SUA)was improved before treatment.On the basis of routine treatment of heart failure without other urate-lowering drugs,patients were observed for 3 and 6 months after receiving valsartan or ARNI.Results: 1.Through the comparison and analysis of the data before treatment between the control group and the observation group showed that the basic data of the two groups of patients were similar,and there was no statistical difference;2.Through the comparison between the groups before and after treatment Comparing 3 months and 6months after treatment,it was found that the average level of uric acid in the control group was 596.95 μmol/L before treatment,and the average level of uric acid in the observation group was 597.06 μmol/L,t=0.005,P=0.996,the difference between the two was not significant.It is statistically significant,and it is considered that the two maintain the same level of uric acid before undergoing different treatment measures.Three months after treatment,the level of uric acid in the control group had no significant change to 596.98 μmol/L,which was no significant change compared with that before treatment(P>0.05).The average level of uric acid in the observation group decreased to 432.60 μmol/L,which was significantly different from that before treatment(P<0.05).And there was a significant difference in the decrease of uric acid between the two,t=5.681,P<0.001.Six months after treatment,the uric acid level in the control group decreased to 534.27 μmol/L,which was significantly different from that before treatment(P<0.05).The uric acid level in the observation group decreased to380.01 μmol/L,which was significantly different from that before treatment(P<0.05).And there was a significant difference in the decrease of uric acid between the two,t=5.365,P<0.001.In terms of creatinine,the average level of creatinine in the control group was 122.95 μmol/L before treatment,and the average creatinine level in the observation group was 120.88 μmol/L,t=0.227,P=0.821.The difference between the two was not statistically significant.Creatinine remained at the same level before undergoing different treatment measures.Three months after treatment,the average level of creatinine in the control group did not change significantly to 124.39 μmol/L,which was no significant change compared with before treatment(P>0.05),and the average level of creatinine in the observation group decreased to 114.42 μmol/L.But there was no statistical significance(P>0.05),and there was no significant difference in the decrease of creatinine between the two,t=1.118,P>0.05.Six months after treatment,after treatment,the creatinine level in the control group had no significant change to122.22 μmol/L,which was no significant change compared with before treatment(P>0.05),and the creatinine level in the observation group decreased to 117.51μmol/L,but There was no statistical significance(P>0.05),and there was no significant difference in the decrease of creatinine between the two groups,t=0.441,P>0.05.Conclusion: Sacubitril valsartan can reduce the serum uric acid level for patients with chronic heart failure complicated with hyperuricemia without influencing renal founction,and it can be given priority in clinical practice for patients with chronic heart failure complicated with hyperuricemia,and can reduce the initiation of uric acid-lowering-related treatments. |
PDF Full Text Request